A two-year randomised trial in 1,260 older adults at risk of dementia found no clear evidence that starting blood markers altered cognitive benefits.A two-year randomised trial in 1,260 older adults at risk of dementia found no clear evidence that starting blood markers altered cognitive benefits.
False-negative blood results occurred in 5.6% of participants compared with false positives in 2.8%, with mismatches tied to kidney function, BMI, and clinical stage.False-negative blood results occurred in 5.6% of participants compared with false positives in 2.8%, with mismatches tied to kidney function, BMI, and clinical stage.